Immunovant, Inc. insider trading
Every open-market purchase and sale by Immunovant, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Immunovant, Inc.’s insiders pay?
From November 12, 2019 to October 30, 2026, 18 insiders reported 25 open-market purchases and 154 sales not made under a pre-set plan in Immunovant, Inc. Twelve months after each purchase was reported, the shares were +195.0% against the S&P 500 on average (median +293.1%), over 24 purchases with a full year of prices; 63% beat the index. After sales, the shares moved −4.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 13, 2019 into $32,334 by November 2, 2026, +18.4% a year. It held shares 95% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $28,941 (+16.5% a year), and held throughout $27,048 (+15.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Salzmann Peter | Chief Executive Officer | 0 | — | — | 27 | +3.3% (26) | April 17, 2025 |
| Barnett Eva Renee | Chief Financial Officer | 0 | — | — | 24 | +1.2% (24) | April 17, 2025 |
| Stout Jay S | Chief Technology Officer | 0 | — | — | 19 | +21.2% (10) | October 23, 2026 |
| Butchko Julia G. | Chief Development Officer | 1 | −112.1% (1) | 0% | 16 | −14.9% (15) | August 23, 2024 |
| Levine Mark S. | Chief Legal Officer | 0 | — | — | 17 | −31.7% (17) | November 22, 2024 |
| Macias William L. | Chief Medical Officer | 0 | — | — | 16 | −17.7% (16) | February 21, 2025 |
| Wong Roderick | Chief Executive Officer | 12 | +343.1% (12) | 100% | 0 | — | December 13, 2019 |
| Geffner Michael | Chief Medical Officer | 0 | — | — | 11 | +13.2% (11) | October 24, 2025 |
| Gloria Melanie | Chief Operating Officer | 0 | — | — | 8 | — | October 9, 2026 |
| Van Tuyl Christopher | Chief Legal Officer | 0 | — | — | 8 | — | October 9, 2026 |
| Roivant Sciences Ltd. | Director | 6 | +4.1% (5) | 20% | 0 | — | December 12, 2025 |
| Girao Tiago | Chief Financial Officer | 0 | — | — | 4 | — | October 30, 2026 |
| Venker Eric | Chief Executive Officer | 0 | — | — | 3 | — | October 5, 2026 |
| Fromkin Andrew J. | Director | 1 | −28.3% (1) | 0% | 1 | — | May 29, 2026 |
| Pande Atul | Director | 2 | +119.2% (2) | 50% | 0 | — | October 4, 2022 |
| Hughes Douglas J. | Director | 1 | −29.3% (1) | 0% | 0 | — | August 30, 2021 |
| Migausky George V | Director | 1 | −20.6% (1) | 0% | 0 | — | August 20, 2021 |
| Torti Frank | Director | 1 | +494.4% (1) | 100% | 0 | — | September 29, 2022 |
When several insiders traded Immunovant, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Immunovant, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −13.7% against the index. After 4 selling crowds, +3.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 3 selling | +38.6% | +18.1% | not yet |
| November 28, 2025 | 3 selling | +10.8% | +16.3% | not yet |
| January 31, 2023 | 5 selling | +0.8% | +15.0% | +80.8% |
| October 31, 2022 | 3 buying | +55.6% | +65.3% | +187.7% |
| January 31, 2022 | 4 selling | −26.6% | −34.4% | +167.6% |
| August 31, 2021 | 4 buying | −12.3% | −33.9% | −29.3% |
| September 30, 2020 | 2 buying | +28.6% | −72.6% | −105.3% |